Age is an independent prognostic factor, as well as the most significant predictor of PFS in HR + /HER2- MBC; patients younger than 60 years old have shorter PFS, which is consistent with previous research results, thereby supporting the hypothesis that breast cancer in younger women exhibits more aggressive behavior, even within HR + /HER2- tumors. Here, ERBB2 is linked to breast cancer.